| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL0482 | Name | ESRG | Aliases | HESRG | |
| Species | Homo sapiens | Chromosome | 3 | Start site | 54632122 | |
| End site | 54639857 | Chain | minus | Exon NO. | 4 | |
| Assembly | Ensembl Release 89 | Class | sense intronic | NCBI accession | NR_027122 | |
| Ensembl | ENSG00000265992 | Sequence | ||||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| intracranial aneurism | N/A | N/A | N/A | expression | HESRG was expressed strongly and diffusively in the nuclei of tumor cells in intracranial germinoma and embryonal carcinoma as well as in human embryonic stem cells.In germinomas, 25 of 31 showed intensive (3+) expression, four cases showed moderate (2+) immunostaining and the remaining 2 cases showed weak (1+) immunostaining. | 21861197 | LncRNADisease Lnc2Cancer | ||
| embryonal carcinoma | qPCR etc. | central nervous system tumor tissue, cell lines (H1, H9) | up-regulated | expression | HESRG was expressed strongly and diffusively in the nuclei of tumor cells in intracranial germinoma and embryonal carcinoma as well as in human embryonic stem cells.In embryonal carcinoma, 6 of 9 showed intensive (3+) immunostaining and 3 of 9 showed moderate (2+) immunostaining. | 21861197 | LncRNADisease Lnc2Cancer | ||